Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $14.00

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $14.00.

A number of equities research analysts have weighed in on ALXO shares. UBS Group decreased their price target on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Lifesci Capital downgraded shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th.

ALX Oncology Trading Down 1.8 %

Shares of ALX Oncology stock opened at $2.18 on Friday. The company’s fifty day simple moving average is $3.84 and its 200-day simple moving average is $9.06. The company has a market cap of $113.58 million, a price-to-earnings ratio of -0.59 and a beta of 1.01. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. ALX Oncology has a 1 year low of $1.88 and a 1 year high of $17.83.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.01. As a group, sell-side analysts expect that ALX Oncology will post -3.04 EPS for the current year.

Insider Activity

In other news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the completion of the sale, the insider now owns 593,447 shares of the company’s stock, valued at approximately $4,688,231.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 28,398 shares of company stock valued at $200,043. 33.40% of the stock is owned by insiders.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co bought a new stake in ALX Oncology in the 1st quarter valued at $27,000. EntryPoint Capital LLC bought a new position in ALX Oncology during the 1st quarter worth $32,000. China Universal Asset Management Co. Ltd. increased its position in ALX Oncology by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after buying an additional 3,825 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after buying an additional 5,200 shares during the period. Finally, Rhumbline Advisers increased its position in ALX Oncology by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after buying an additional 5,360 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.